Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIM104
- Development stage
- Preclinical
- Lead developer
- CiMaas
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CIM104 is an allogeneic natural killer (NK) cell therapy candidate being developed by CiMaas for the treatment of solid tumors, with a primary focus on breast cancer. The therapy is part of CiMaas's CIM100 series, which utilizes a proprietary expansion and activation platform to generate large quantities of highly cytotoxic NK cells from healthy donor blood. This "off-the-shelf" approach aims to overcome the limitations of autologous cell therapies by providing immediate treatment availability. CIM104 consists of activated NK cells that are designed to recognize and eliminate malignant cells through natural cytotoxicity receptors and the release of cytotoxic granules containing perforin and granzymes. The asset is currently in the preclinical stage of development.
- Other names
- CIM104-CiMaas-NK cell therapyCIM-104-CiMaas-NK cell therapyCIM 104-CiMaas-NK cell therapy
Beyond the preview
Go deeper on CIM104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIM104.